A Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
Latest Information Update: 18 Feb 2026
At a glance
- Drugs ONC 783 (Primary)
- Indications Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions; First in man
- Sponsors OncoC4
Most Recent Events
- 18 Feb 2026 New trial record